Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
…
continue reading
Er Positive Breast Cancer Podcasts
Breast Cancer Conversations is a podcast produced by Survivingbreastcancer.org where we inject positivity into the very fabric of a breast cancer diagnosis. Breast Cancer Conversations provides education, and inspiration, and offers hope. You will hear stories from those diagnosed with breast cancer, interviews with medical professionals, and thought-leadership emerging from the oncology field. Welcome to our breast cancer community! Welcome to the conversation.
…
continue reading
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
…
continue reading
Hear from experts as they discuss timely clinical topics as well as relevant and actionable strategies for practice improvement. This podcast is available for CME credit.
…
continue reading
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
…
continue reading
1
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
41:17
41:17
Play later
Play later
Lists
Like
Liked
41:17
Featuring an interview with Prof Patrick Neven, including the following topics: Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00) Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57) Emerging data with novel oral SERD combinations (6:31) Challenges for a general medical oncologist in br…
…
continue reading
1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
21:21
21:21
Play later
Play later
Lists
Like
Liked
21:21
Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;…
…
continue reading
1
Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
21:21
21:21
Play later
Play later
Lists
Like
Liked
21:21
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
…
continue reading
1
Endometrial Cancer — Clinical Investigator Perspectives on Actual Patient Cases
1:00:18
1:00:18
Play later
Play later
Lists
Like
Liked
1:00:18
Featuring perspectives from Dr Kathleen N Moore and Dr Matthew A Powell, including the following topics: Introduction: A Pan-tumor Perspective on Microsatellite Instability (MSI)-High Disease — Immunotherapy for Localized Disease (0:00) Case: A woman in her early 60s with mismatch repair-deficient metastatic endometrial cancer (EC) and multiple pos…
…
continue reading
1
Endometrial Cancer — Clinical Investigator Perspectives on Actual Patient Cases
1:00:17
1:00:17
Play later
Play later
Lists
Like
Liked
1:00:17
Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. CME information and select publications here.…
…
continue reading
1
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
41:17
41:17
Play later
Play later
Lists
Like
Liked
41:17
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
…
continue reading
1
ESR1 Mutation Testing in Breast Cancer: Setting the Standard for Personalized Oncology?
24:37
24:37
Play later
Play later
Lists
Like
Liked
24:37
Is your patient progressing on an aromatase inhibitor (AI)? Fine-tune ddPCR/NGS testing to detect resistance and optimize oral selective estrogen receptor degrader (SERD) success. Credit available for this activity expires: 11/04/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/esr1-mutation-testing-breast-…
…
continue reading
1
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)
42:37
42:37
Play later
Play later
Lists
Like
Liked
42:37
Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics: Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00) Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34) Util…
…
continue reading
1
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
41:17
41:17
Play later
Play later
Lists
Like
Liked
41:17
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
…
continue reading
